We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

73 hedge funds and large institutions have $217M invested in BioCryst Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

755% more capital invested

Capital invested by funds: $25.4M → $217M (+$192M)

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

64% more call options, than puts

Call options by funds: $4.96M | Put options by funds: $3.02M

16% more funds holding

Funds holding: 63 → 73 (+10)

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

Holders
73
Holders Change
+10
Holders Change %
+15.87%
% of All Funds
2.37%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
25
Increased
17
Reduced
20
Closed
15
Calls
$4.96M
Puts
$3.02M
Net Calls
+$1.94M
Net Calls Change
+$1.99M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$29.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.3M
3
DM
Deerfield Management
New York
+$8.28M
4
VM
VHCP Management
New York
+$5.92M
5
BBA
Baker Bros. Advisors
New York
+$5.76M

Top Sellers

1
Northern Trust
Northern Trust
Illinois
-$1.99M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.65M
3
TC
TFS Capital
Pennsylvania
-$1.13M
4
Deutsche Bank
Deutsche Bank
Germany
-$917K
5
Barclays
Barclays
United Kingdom
-$726K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$48.8M +$5.76M +1,136,364 +20%
RCM
2
RA Capital Management
Massachusetts
$42.5M +$29.6M +5,844,700 New
Wellington Management Group
3
Wellington Management Group
Massachusetts
$19.2M +$13.3M +2,631,590 New
VM
4
VHCP Management
New York
$15.9M +$5.92M +1,167,214 +115%
Vanguard Group
5
Vanguard Group
Pennsylvania
$12.1M +$243K +47,924 +3%
DM
6
Deerfield Management
New York
$11.9M +$8.28M +1,632,360 New
TC
7
TFS Capital
Pennsylvania
$8.84M -$1.13M -223,167 -16%
BIT
8
BlackRock Institutional Trust
California
$8.48M +$53.2K +10,492 +0.9%
TGHSA
9
TPG Group Holdings (SBS) Advisors
Texas
$8.46M – – –
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$5.99M +$3.79M +748,058 +1,005%
Jennison Associates
11
Jennison Associates
New York
$3.28M +$2.28M +450,000 New
BIM
12
Bogle Investment Management
Massachusetts
$2.81M +$1.96M +386,089 New
SGAM
13
Smith Group Asset Management
Texas
$2.14M -$43.6K -8,600 -3%
Millennium Management
14
Millennium Management
New York
$1.79M +$1.25M +245,592 New
VAM
15
Visium Asset Management
New York
$1.73M +$1.2M +236,900 New
QF
16
QVT Financial
New York
$1.51M +$1.05M +207,034 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.5M +$167K +32,927 +19%
PA
18
Perceptive Advisors
New York
$1.39M +$967K +190,588 New
Goldman Sachs
19
Goldman Sachs
New York
$1.35M -$111K -21,834 -11%
Jane Street
20
Jane Street
New York
$1.32M +$642K +126,569 +230%
BFA
21
BlackRock Fund Advisors
California
$1.08M +$124K +24,350 +20%
EI
22
EAM Investors
California
$1.08M +$751K +148,081 New
California Public Employees Retirement System
23
California Public Employees Retirement System
California
$1.05M -$10.1K -2,000 -1%
FSA
24
Franklin Street Advisors
North Carolina
$1.01M – – –
Two Sigma Investments
25
Two Sigma Investments
New York
$908K +$632K +124,656 New
1
2 3 4

BCRX Hedge Fund Activity: Q3 2013 in Review

73 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2013, worth a combined $217M — up 755% from $25.4M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new BCRX positions and 15 closed out — a net gain of 10 holders — while 17 added to existing stakes and 20 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $29.6M. The largest seller was Northern Trust, cutting an estimated $1.99M.

  • 73 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2013, up from 63 in Q2 2013.
  • Funds reported $217M of BioCryst Pharmaceuticals stock for Q3 2013, up 755% quarter-over-quarter.
  • 25 funds opened new BioCryst Pharmaceuticals positions in Q3 2013 and 15 closed out, a net change of +10 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2013 was RA Capital Management, an estimated $29.6M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2013 was Northern Trust, an estimated $1.99M sold.

Based on aggregated 13F filings for Q3 2013.